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Abstract. Chemoresistance and self-renewal of cancer stem 
cells (CSC), found in many tumors including pancreatic ductal 
adenocarcinoma (PDAC), are believed to underlie tumor mass 
regrowth. The distribution of cells carrying the putative stem-
cell markers CD133, Nestin, Notch1-4, Jagged1 and 2, ABCG2 
and aldehyde dehydrogenase (ALDH1) was assessed immuno-
histochemically using PDAC and normal pancreas tissue 
microarrays. The immunoreactivity was semi-quantitatively 
graded against the normal pancreas and was correlated with 
the differentiation grade and disease stage. No statistical 
significant differences were found between normal pancreas 
and PDAC in the expression of Nestin, Notch1, 3 and 4, 
ABCG2 or ALDH1. Notch2 and Jagged1 and 2 expression 
were increased in PDAC. CD133-positive cells were above-
normal in PDAC, but the difference was not statistically 
significant. Nestin, Notch1-4, Jagged1, ABCG2 and ALDH1 
immunostaining scores were not correlated with tumor grade 
or disease stage. CD133 and Notch2 expression was significantly 
inversely correlated with tumor grade, but not disease stage. 
Notch3 immunostaining positively correlated with tumor 
stage, but not with differentiation grade. Jagged2 protein 
expression correlated inversely with disease stage, but not 
with tumor grade. From the clinical standpoint, improved 
delineation of the tumor CSC signature, putatively responsible 
for tumor initiation and recurrence after initial response to 
chemotherapy, may offer novel therapeutic targets for this 
highly lethal cancer.
Introduction
One of the major challenges in the treatment of pancreatic 
ductal adenocarcinoma (PDAC) is the frequent failure of 
chemotherapy (1). Poor response rates and short progression-
free intervals suggest that pancreatic cancer rapidly develops 
chemoresistance, or possesses it intrinsically. The lack of 
success with existing strategies underscores the importance of 
continued research efforts, in the hope of developing novel 
therapeutic strategies for the treatment of patients diagnosed 
with PDAC.
The cancer stem cell (CSC) theory (2) has given rise to a 
paradigm shift in how cancer biologists think about solid 
organ tumors. Underlying this increasingly-accepted concept 
is the hypothesis that, just as in organs and tissues, normal 
stem cells are at the apex of the hierarchical scheme that 
drives organogenesis, likewise cancer cells possessing the 
properties of stem cells may be key drivers of the complex 
machinery underlying tumorigenesis, since tumors themselves 
may function as complex organs.
Emerging data have shown that tumors are quite hetero-
geneous, and that they are composed of a small subset of 
distinct cancer cells, i.e. CSC, which are responsible for tumor 
initiation and propagation. These CSC, like their normal 
counterparts, possess the ability to self-renew, to produce 
differentiated progeny and, most notably, to survive adverse 
conditions in the tissue microenvironment (3). CSC were first 
discovered in the hematopoietic system (4) and have subsequently 
been identified in several solid tumors originating from the 
breast (5), brain (6), colon (7,8), prostate (9,10) and lung (11). 
Recently, using a xenograft model, a subpopulation of highly 
tumorigenic cancer cells has been identified within human 
PDAC; these cells express the cell surface markers, CD44, 
CD24, and the epithelial-specific antigen (ESA), and display 
several features typically seen in stem cells, including the 
ability to self-renew, to generate differentiated progeny, and to 
recapitulate the phenotype of the tumor from which they were 
derived (12,13).
In normal adult tissues, proper homeostatic tissue mainte-
nance of stem cells is dependent on the integration of both 
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cell-intrinsic and cell-extrinsic factors, and is achieved by the 
maintainance of a delicate balance between self-renewal and 
differentiation. The stem-cell niche has been envisaged to be a 
physiological microenvironment consisting of specialized cells 
that physically anchor the stem cell and provide the necessary 
factors to maintain its stemness (14). In light of the significant 
role played by the normal stem-cell niche in determining the 
cells' fate, it has been proposed that a CSC niche exists and 
that interactions with this tumor niche may play a similar role 
in specifying a self-renewing population of tumor cells.
Considerable effort is being expended in the search for 
markers of stem cells: collectively, these marker molecules 
appear to be involved in maintaining stemness, and in ensuring 
adhesion to the stem-cell niche; they may also be involved in 
cytoprotection (15). The phenotypic characterization of CSC 
is still debated. CD133, Nestin, Notch1-4, Jagged 1 and 2, 
ABCG2 and aldehyde dehydrogenase (ALDH1) are recognized 
as biomarkers that represent the stemness phenotype. 
Since the feasibility of targeting the CSC niche therapeutically 
will at least in part depend on the degree of similarity between 
normal and CSC niches, the study used immunohistochemical 
methods to characterize the tissue distribution of these 
proteins, in formalin-fixed, paraffin-embedded human PDCA 
tissue, and to compare the findings with the distribution in 
normal human pancreas.
Materials and methods
PDAC tissue microarrays. Tumor specimens from 37 PDAC 
patients plus 6 samples of normal pancreatic tissue were 
analyzed. PDAC tissue microarrays (TMA) were obtained 
from Pantomics, (Richmond, CA) (duplicate cores per case: 
20 cases of ductal adenocarcinoma and 3 cases of normal 
pancreatic tissue) and from US Biomax (Rockville, MD) 
(triplicate cores per case, 17 cases of ductal adenocarcinoma 
and 3 cases of normal pancreatic tissue). Patient characteristics 
are summarized in Table I. Tissues were fixed in formalin and 
embedded in paraffin. TMA were validated by hematoxylin 
and eosin staining.
Immunohistochemistry. Tissue fragments were melted into 
the acceptor paraffin block by heating the block for 30 min at 
60˚C. Samples were deparaffinized in xylene and rehydrated 
in a graded series of alcohols; the antigen was then retrieved 
in Tris/EDTA buffer (10 mmol/l Tris Base, 1 mmol/l EDTA, 
pH 9.0) using a pressure cooker. The sections were treated 
with a 3% solution of H2O2 for 5 min to inhibit endogenous 
peroxidase activity. After 1 h pre-incubation in a blocking 
buffer (5% normal goat serum in phosphate-buffered saline) 
to prevent non-specific staining, the sections were incubated 
with primary antibodies (Table II), for 45 min. The sections 
were then treated with the appropriate biotinylated secondary 
antibodies, followed by incubation with an avidin-biotin 
peroxidase complex solution, for 30 min, and diaminobenzidine 
tetrahydrochloride as a chromogen. The slides were finally 
counterstained with Mayer's hematoxylin for 5 sec, dehydrated, 
and mounted in Clarion (Biomeda, Foster City, CA, USA).
Analysis of immunohistochemical expression patterns. The 
staining intensity was evaluated by a semi-quantitative 
method using the immunoreacting score (IRS) proposed by 
Remmele and Stegner (16) in which IRS = SI (staining intensity) 
x PP (% of positive cells). SI was assigned as: 0, negative; 1, 
weak; 2, moderate; 3, strong. PP was assigned as: 0, negative; 
1, 1-20% positive cells; 2, 21-50% positive cells; 3, 51-100% 
positive cells. Ten visual fields from different areas of each 
specimen were chosen at random for IRS evaluation, and the 
scores were averaged.
Statistical analysis. All results are expressed as median and 
range. The immunostaining scores of different stem cell markers 
in pancreatic carcinoma were compared with the scores in 
normal pancreas. Statistical analysis was performed using the 
non-parametric Mann-Whitney test to compare variables. The 
correlation between different parameters was analyzed using 
the non-parametric Spearman correlation coefficient; p-values 
of <0.05 were considered to indicate statistical significance. 
All statistical analyses were performed using the SigmaStat 
software (Jandel Scientific, San Rafael, CA, USA). 
Results
Distribution of CD133, Nestin, Notch (1-4), Jagged1 and 2, 
ABCG2 and ALDH1 in normal pancreas and PDAC. The 
distributions of CD133, Nestin, Notch (1-4), Jagged 1 and 2, 
ABCG2 and ALDH1 are summarized in Tables III and IV; 
representative staining profiles are in Fig. 1. 
CD133. Immunoreactivity was observed in the center of 
the normal acini and in neoplastic ductal structures in a 
basilar pattern, defined by staining at the apical membrane of 
the cells. Staining was not seen in any specimen in the islets 
of Langerhans. Immunoreactivity to CD133 was retained in 
29.7% (11/37) cases of PDCA, while expression was lost in 
70.3% of cases (26/37). In the positive cases, the area and 
intensity of expression varied along with the morphological 
heterogeneity of the tumor. No statistically-significant 
Table I. Clinical characteristics of the patients.
Pancreas ductal adenocarcinoma, N 37
 Gender (male/female) 15/22
 Age (median, range) 54 (31-79)
 Histological grading, N
  Well-differentiated (G1)   7
  Moderately differentiated (G2) 15
  Poorly differentiated (G3) 15
 Stage (UICC staging system), N
  I 11
  IIA 10
  IIB   9
  III   0
  IV   7
Normal pancreas, N   6
 Gender (male/female) 3/3
 Age (median, range) 46 (35-58)
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Table II. Antibodies used in immunohistochemistry.
Antigen Antibody species Manufacturer Dilution
CD133/1 Mouse monoclonal Miltenyi BioTec, Bergisch Gladbach, Germany 1:50
Nestin Mouse monoclonal Santa Cruz Biotechnology, Santa Cruz, CA 1:50
Notch1 Goat polyclonal Santa Cruz Biotechnology 1:100
Notch2 Rabbit polyclonal Santa Cruz Biotechnology 1:500
Notch3 Rabbit polyclonal Santa Cruz Biotechnology 1:100
Notch4 Rabbit polyclonal Santa Cruz Biotechnology 1:100
Jagged1 Goat polyclonal Santa Cruz Biotechnology 1:500
Jagged2 Rabbit polyclonal Santa Cruz Biotechnology 1:100
ABCG2 Mouse monoclonal Chemicon International, Temecula, CA 1:30
ALDH1 Rabbit monoclonal Abgent, San Diego, CA 1:25
Figure 1. Differential expression of Nestin, Notch2, Jagged1 and Jagged2 proteins in normal pancreas and pancreatic ductal adenocarcinoma (PDAC) tissue 
specimens as determined by immunohistochemistry. Specimens are representative examples of 6 non-tumoral and 37 tumoral pancreas tissue samples 
(original magnification, x250).
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difference was detected in the IRS between the normal 
pancreas and positive PDAC [median (range): 1 (1-2) vs. 1 
(0.5-3), p=0.186)].
Nestin. No immunostaining was seen in acinar cells nor in 
islets of Langerhans of normal pancreas nor in neoplastic 
ductal cells. Nestin was identified in some pancreatic capillary 
endothelial cells and in nerve fibers within the islets in normal 
pancreas, and in either invading cells or in cells adjacent to 
cancer cells in all PDAC cases. Significant differences in IRS, 
calculated in positive cells, were observed between normal 
and tumor pancreas (median (range) 0 (0-0.667) vs. 0.5 (0-1.5), 
p=0.006).
Notch1. In normal pancreas, positive cells were identified 
in the acini and also in the cells of the islets of Langerhans. 
Notch1 expression was identified in 94.6% of PDAC specimens 
(35/37). Immunostaining was observed in the cytoplasm of 
neoplastic ductal structures. No statistically-significant 
difference was detected in IRS between normal pancreas and 
PDAC; median (range): 3 (0-4) vs. 3 (0-9), p=0.186).
Notch2. No immunostaining was seen in normal pancreas 
(acinar cells nor islets of Langerhans). Notch2 expression in 
PDAC was identified in 51.3% of specimens (19/37). Immuno-
staining was observed in the cytoplasm of neoplastic ductal 
structures.
Notch3. In the normal pancreas, Notch3 expression was 
identified in the cytoplasm of cells of the islets of Langerhans 
and acinar cells, with immunostaining intensity being stronger 
in the latter. Notch3 expression was found in 37.8% of PDAC 
specimens (14/37). Cytoplasmic and nuclear immunostaining 
was identified in neoplastic ductal structures. No significant 
differences in IRS between normal and positive PDAC were 
observed; median (range): 2 (0-6) vs. 2 (0-7.5), p=0.385).
Notch4. In normal pancreas, Notch4-positive cells were 
only identified in the cells of the islets of Langerhans. No 
positive acinar cells were seen. Expression was not identified 
in any PDAC specimens.
Jagged1. In normal pancreas, Jagged1-positive cells were 
focally identified in the acini, whereas cells of the islets of 
Table IV. Correlation among the immunoreacting score of 
different stem cell markers, differentiation grading and disease 
staging.
 Differentiation grade Disease stage
 ––––––––––––––––– –––––––––––––––
Markers ra p r p
CD133 -0.357 0.030 -0.102 0.545
Nestin 0.193 0.250 0.069 0.682
Notch1 0.0001 0.999 0.046 0.786
Notch2 0.482 0.003 0.108 0.521
Notch3 0.103 0.544 0.373 0.023
Notch4 -0.260 0.120 0.147 0.384
Jagged1 -0.013 0.937 0.273 0.102
Jagged2 -0.010 0.950 -0.456 0.005
ABCG2 -0.172 0.308 -0.148 0.380
ALDH1 0.245 0.143 0.282 0.090
aSpearman rank order correlation test.
Table III. Summary of stem cell marker expression in normal pancreas and in pancreatic adenocarcinoma.
 Normal pancreas Pancreatic adenocarcinoma –––––––––––––––––––––––––––––––––– ––––––––––––––––––––––––––––––––––––––––––––––––––––
Antigen Localization IRS Localization IRS % (#)
  median (range)  median (range)
CD133 Acinar cells    1 (1-2) Neoplastic ductal structures 1 (0.5-3) 29.7 (11/37)
Nestin Capillary endothelial    0 (0-0.667) Capillary endothelial cells 0.50 (0-1.5) 100  (37/37)
 cells and nerve fibers   and nerve fibers
Notch1 Acinar and islets of    3 (0-4) Neoplastic ductal structures 3 (0-9) 94.6 (35/37)
 Langerhans cells
Notch2     0  Neoplastic ductal structures 0.33 (0-6) 51.3 (19/37)
Notch3 Acinar and islets of    2 (0-6) Neoplastic ductal structures 2 (0-7.5) 37.8 (14/37)
 Langerhans cells
Notch4 Islets of Langerhans cells      0 (0-2) Islets of Langerhans cells 0 (0-2) 100  (37/37)
Jagged 1 Acinar cells    0 (0-1) Neoplastic ductal structures 0.75 (0-3.7) 40.5 (15/37)
Jagged 2     0  Non-neoplastic exocrine 1 (0-6) 67.6 (25/37)
    pancreas adjacent to ductal
    adenocarcinoma cells
ABCG2 Acinar cells    0 (0-0.33) Neoplastic ductal structures 0 (0-1) 5.4   (2/37)
ALDH1 Acinar and islets of 1.5 (1-3) Neoplastic ductal structures 1 (0-4) 29.7 (11/37)
 Langerhans cells
ONCOLOGY REPORTS  27:  69-76,  2012 73
Langerhans were negative. Expression was identified in 40.5% 
of PDAC specimens (15/37). Immunostaining was observed in 
the cytoplasm of neoplastic ductal structures. A statistically-
significant increase in IRS was found in positive PDAC vs. 
normal pancreas. The median (range) was 0.750 (0-3.7) in 
PDAC vs. 0 (0-1) in normal (p=0.040).
Jagged2. In normal pancreas, immunostaining for Jagged2 
was negative in both exocrine and endocrine components. 
Expression was identified in 67.6% of PDAC specimens 
(25/37). Immunostaining was observed in the cytoplasm of 
neoplastic ductal structures. Interestingly, acinar cells were 
positive in non-neoplastic exocrine pancreas adjacent to ductal 
adenocarcinoma cells; IRS median range: 1 (0-6).
ABCG2. Weak cytoplasmic staining was focally seen in 
the acinar cells of the normal pancreas. Occasional ABCG2-
positive cells were identified in 5.4% of PDAC specimens 
(2/37). Immunostaining was identified in the tumor-cell 
cytoplasm. Normal endocrine islets were negative. Similar 
IRS values were observed between normal and PDAC 
specimens; median (range): 0 (0-0.33) vs. 0 (0-1), p=0.919.
ALDHI. In normal pancreas, ALDH1-positive cells were 
focally identified in the acini. Expression was identified in 
29.7% of PDAC specimens. Immunostaining was observed in 
the cytoplasm of neoplastic ductal structures. Cells of the 
islets of Langerhans were also positive, particularly in the 
areas containing β-cells (insulin production). No significant 
differences were found between normal and positive tumor 
pancreas specimens; median (range): 1.5 (1-3) vs. 1 (0-4), 
p=0.125.
Correlation among stem cell marker expression, differen-
tiation grading and disease staging. The correlation among IRS 
of different stem cell markers evaluated in tumor tissues, 
differentiation grading, and disease staging, was calculated by 
the Spearman rank order correlation test (Table IV). CD133 
protein expression was inversely and significantly correlated 
with tumor differentiation grading (p=0.03), but not with tumor 
stage (p=0.545). Notch1, Notch4, Jagged1, ABCG2 and ALDH1 
IRS were not associated with either tumor differentiation grade 
(p=0.999, p=0.937, p=0.120, p=0.308, p=0.143, respectively) or 
tumor stage (p=0.786, p=0.384, p=0.102, p=0.380, p=0.090, 
respectively). Notch2 protein expression was positively 
correlated with differentiation grade (p=0.003), but not with 
tumor stage (p=0.521). A positive correlation was found between 
Notch3 immunostaining and tumor stage (p=0.023), but not 
with differentiation grade (p=0.544). By contrast, Jagged2 
protein expression was inversely correlated with tumor stage 
(p=0.005), but was not correlated with tumor differentiation 
grade (p=0.950).
Discussion
It has recently been reported that, in addition to initiating and 
sustaining tumor growth, CSC may also mediate cancer drug 
resistance, relapse and metastasis; this has been found to 
occur in several human malignancies, including PDAC. 
Nevertheless, little is known about the expression of CSC 
markers in situ, especially in relation with normal pancreas 
and the tumor's grade of malignancy. To address this problem, 
we investigated the concomitant expression of ten proteins: 
CD133, Nestin, Notch1, Notch2, Notch3, Notch4, Jagged1, 
Jagged2, ABCG2 and ALDH1, which are the most widely-
accredited markers for identification of CSC. 
The expression of CD133 (human prominin-1), originally 
identified as a cell-surface antigen present in CD34+ hemato-
poietic stem cells, is one criterion which has been used to 
identify putative CSC in solid tumors, such as brain (6,17), 
lung (18), skin, melanoma (19), prostate (10), kidney (20) colon 
(7,8) and liver (21).
In our series of cases, CD133 expression was increased in 
PDAC vs. normal pancreatic epithelial cells, although statistical 
significance was not achieved. Moreover, we found this 
marker to be inversely associated with tumor differentiation 
grade, in line with studies reporting both the presence of 
CD133 in different types of stem cells and in several solid 
tumors, and its down-regulated expression in differentiated 
cells (22). In particular, it has been demonstrated that CD133 
is a marker of putative pancreatic progenitor cells during 
embryogenesis (23). The localization of the CD133 marker on 
the apical cell surface, in both normal and tumor tissues, 
suggests its involvement in the mechanisms influencing cell 
polarity, migration and interaction of stem cells with 
neighboring cells and/or the extracellular matrix, although 
experimental data are not yet available. Side populations of 
cells with stem-cell characteristics, isolated from human 
pancreatic carcinoma cells, show significantly higher levels of 
mRNA expression for CD133 and have high resistance to 
gemcitabine treatment, a chemotherapeutic drug currently 
used in clinical settings against aggressive PDAC (24).
Nestin, originally described as a neuronal stem cell/
progenitor cell marker during central nervous system develop-
ment (25,26), was initially described in the adult pancreas as a 
specific marker of a cell subpopulation having a possible 
stem-cell function (27). 
In agreement with other reports (28,29), the immuno-
histochemical studies to characterize Nestin expression in the 
normal pancreas and in PDAC showed that Nestin was 
localized in a few capillary endothelial cells and nerve fibers 
within the islets of normal pancreatic tissues and in numerous 
capillary endothelial cells and nerve fibers invading the tumor 
area in PDAC. Despite the Nestin cellular localization revealed 
by immunohistochemistry, lineage-tracing experiments indicate 
that the cells derived from Nestin-expressing progenitor cells 
are mostly exocrine cells (30,31). Moreover, in rodents, 
Nestin-expressing cells contribute to the regenerative capacity 
of the exocrine pancreas, after partial pancreatectomy and 
during recovery from acute pancreatitis (32). In a mouse 
model, it has been demonstrated that activation of oncogenic 
K-ras in the Nestin cell lineage is sufficient to initiate 
pancreatic intraepithelial neoplasia lesions (PanINs), putative 
precursors to PDAC (33), suggesting that these cells may be 
the elusive progenitor population from among which PDAC 
arises.
During development of the pancreas, differentiation of 
epithelial precursors is tightly regulated by Notch signaling, a 
highly conserved pathway known to regulate cell-fate decisions 
in a variety of organisms (34). In vertebrates there are four 
Notch transmembrane receptors, Notch 1, 2, 3 and 4, whose 
activities are controlled by the family ligands, Delta-like and 
Jagged (Jagged1 and Jagged2) (35). Moreover, mechanistically, 
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increased Notch signaling is associated with chemoresistance, 
and with the epithelial-mesenchymal transition (EMT) chara-
cteristic of pancreatic carcinoma cells (36).
Among the four members of the Notch protein family, we 
found that Notch1 and Notch4 were similarly expressed in 
normal and tumor tissues, and were not correlated to either 
tumor differentiation grade or stage. Interestingly, though, 
cytoplasmic Notch2 expression was identified in approximately 
50% of PDAC cells, but not in their normal counterparts, and 
there was a positive correlation with the grade of tumor 
differentiation. It has been reported that immortalized human 
pancreatic Nestin-expressing cells, after transfection with 
cDNA of the catalytic subunit of telomerase (hTERT-HPNE), 
have properties identical to those of the intermediary cells 
observed during acinar-to-ductal metaplasia (37), and that 
unlike their native counterparts they express Notch2 (38). By 
contrast, Notch3 protein was not differentially expressed in 
quantitative terms in PDAC vs. normal pancreas. However, in 
tumors, its expression was correlated with disease stage, 
suggesting that Notch3 is mechanistically linked with a more 
malignant phenotype.
Notch signaling is activated through the interaction of 
Notch receptors with Delta-like and Jagged ligands on 
neighboring cells (39). It consists of two cleavages, occurring 
at the extracellular side, followed by a third cleavage that 
liberates the intracellular Notch receptor domain, which is 
translocated to the cell nucleus (40,41), where it regulates the 
balance between cell differentiation and stem cell proliferation, 
during the development of numerous tissues, including the 
pancreas (34,42). It is likely that this latter form participates in 
neoplastic cell transformation in several organs, such as the 
cervix, uteri, lung, breast, nerve tissue and also in the pancreas 
(43-47). However, the cases of staining in PDAC that we found 
were uniformly cytoplasmic, with no nuclear Notch2 and 
Notch3 being observed in any case; it is thus likely that tumors 
expressing nuclear Notch2 and Notch3 had been found to be 
non-resectable.
We found that both Jagged1 and Jagged2 ligands were 
more strongly expressed in tumor lesions that in normal tissue 
counterparts. In our series of tissues, Notch2 and Notch3 
receptors were up-regulated in the tumor specimens. Thus, 
Notch can be reactivated in pancreatic tumors and may 
potentially be linked to stemness acquisition and to EMT 
(36).
CSC have been hypothesized to be resistant to conventional 
chemotherapy and radiation therapy, and are thought to be the 
culprits behind cancer metastasis and recurrence after clinical 
remission. The ABC transporter family ABCG2 functions as 
a high-capacity drug transporter with wide substrate specificity 
(48). Expression of ABCG2 is observed not only in adult stem 
cells but also in primary cancer cells and cell lines, where it 
confers a multidrug resistant phenotype, although its precise 
physiological role in stem cells is still unclear (49). In our 
study, we identified ABCG2-positive cells only occasionally 
and in only a few PDAC patients, with IRS values similar to 
those of normal pancreas, in agreement with what has been 
reported by König et al (50). 
ALDH1 is part of a group of NAD(P)+-dependent enzymes 
involved in oxidizing a wide variety of aldehydes into their 
corresponding carboxylic acids (51). ALDH1 activity identifies 
normal stem cells and tumor-initiating cells (i.e. CSC) in 
several human malignancies, where it seems to play an important 
role in drug resistance, cell proliferation, differentiation and 
response to oxidative stress (52-54). It is reported that ALDH1 
is required for development of the pancreas during mouse 
embryogenesis, and is associated with tumorigenic pancreatic 
cancer cells both in vitro and in vivo. We found that the 
majority of primary tumor specimens lacked expression of 
ALDH1-positive cells (70%), while this protein was widely 
expressed in normal pancreas specimens. This is in contrast 
with a recent study (55) that found high expression of ALDH1 
in PDCA. This discrepancy might be due to variability in 
tumor sampling, or it could be that tumors are phenotypically 
and functionally distinct in terms of CSC.
Although an optimal enumeration technique has not yet 
been determined, and consensus has not yet been reached 
concerning the phenotypic definition of CSC, clinical studies 
assessing these cells in cancer patients are increasingly being 
reported. However, inter-laboratory variability, resulting from 
doubt over the definition of CSC, and different technical 
methods (e.g., antigen retrieval and detection methods) used in 
the different studies, make comparison among different reports 
difficult.
It is clear that additional research is needed to increase our 
understanding of the molecular machinery underlying the 
regulation of cell self-renewal and resistance to chemotherapy 
and radiation in pancreatic CSC, and that much is yet to be 
learned about the intricacies of the pancreatic cancer micro-
environment and its causes. However, our study points to a 
possible different pattern of frequency and localization of 
CSC markers in PDAC vs. normal pancreas, in particular 
concerning the Notch pathway and Jagged ligands. Improved 
delineation of such a signature would be very important to 
develop targeted combination therapies for selective elimination 
of CSC, having minimal toxicity to normal stem cells, which 
would likely benefit patients suffering from this difficult to 
treat disease.
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